Suppr超能文献

国际注册研究中亚洲人群 CFTR 基因型分析凸显了亚洲囊性纤维化患者诊断和治疗方面的差异。

CFTR genotype analysis of Asians in international registries highlights disparities in the diagnosis and treatment of Asian patients with cystic fibrosis.

机构信息

Department of Pediatrics, Stanford University, Stanford, CA.

Department of Pediatrics, Stanford University, Stanford, CA.

出版信息

Genet Med. 2022 Oct;24(10):2180-2186. doi: 10.1016/j.gim.2022.06.009. Epub 2022 Jul 20.

Abstract

PURPOSE

Cystic fibrosis (CF) is not well-characterized in Asians, potentially resulting in delayed diagnosis and poor prognosis. We characterized CF in Asian subgroups to address these disparities.

METHODS

De-identified ethnicity and CFTR variant data were obtained from the United States, United Kingdom, and Canadian CF registries. We measured the prevalence of CF, CFTR variant allele frequencies, effectiveness of screening panels, and eligibility for modulator therapies.

RESULTS

The prevalence of CF was 1 in 74,982 people (Canada) to 1 in 13,340 people (United Kingdom) for South Asians and 1 in 256,541 (Canada) to 1 in 52,563 (United Kingdom) for other Asians, suggesting 26,000 to 146,000 patients with CF in South Asia. p.(F508del) variant was markedly less frequent in Asians than in non-Hispanic Whites. Splicing and nonsense variants occurred at high allelic frequencies in Asians, resulting in 41% to 49% of South Asians and 21% to 39% of other Asians being ineligible for CFTR modulator therapies. Hologic/EU2v1 panels failed to identify 37% to 47% of South Asian and 23% to 46% of other Asian patients with CF.

CONCLUSIONS

Among Asians, CF appears to be more common in South Asians. A significant CF population may exist in South Asia. CFTR variants in South and other Asians markedly differ from non-Hispanic Whites causing inequities in newborn screening, diagnosis, and treatment. New strategies are necessary to mitigate these health care disparities.

摘要

目的

囊性纤维化(CF)在亚洲人群中的特征不明显,可能导致诊断延迟和预后不良。我们对亚洲亚组的 CF 进行了特征描述,以解决这些差异。

方法

从美国、英国和加拿大 CF 注册处获得了去识别的种族和 CFTR 变体数据。我们测量了 CF 的患病率、CFTR 变体等位基因频率、筛查面板的有效性以及调节剂治疗的资格。

结果

南亚人群中 CF 的患病率为每 74982 人中有 1 例(加拿大)至每 13340 人中有 1 例(英国),而其他亚洲人群中 CF 的患病率为每 256541 人中有 1 例(加拿大)至每 52563 人中有 1 例(英国),提示南亚有 26000 至 146000 例 CF 患者。p.(F508del)变体在亚洲人群中明显比非西班牙裔白人少。剪接和无义变体在亚洲人群中的等位基因频率较高,导致 41%至 49%的南亚人和 21%至 39%的其他亚洲人不符合 CFTR 调节剂治疗的条件。Hologic/EU2v1 面板未能识别 37%至 47%的南亚和 23%至 46%的其他亚洲 CF 患者。

结论

在亚洲人群中,CF 在南亚人群中似乎更为常见。南亚可能存在一个相当大的 CF 人群。南亚和其他亚洲人群的 CFTR 变体与非西班牙裔白人明显不同,导致新生儿筛查、诊断和治疗方面存在不公平现象。需要新的策略来减轻这些医疗保健差异。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验